165 related articles for article (PubMed ID: 35884507)
1. Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Sohn SH; Sul HJ; Kim BJ; Zang DY
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884507
[TBL] [Abstract][Full Text] [Related]
2. Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.
Sohn SH; Sul HJ; Kim B; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825724
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the
Sohn SH; Sul HJ; Kim BJ; Zang DY
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339049
[TBL] [Abstract][Full Text] [Related]
4. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
[TBL] [Abstract][Full Text] [Related]
5. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
6. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
7. Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling.
Sohn SH; Kim B; Sul HJ; Choi BY; Kim HS; Zang DY
Onco Targets Ther; 2020; 13():1027-1035. PubMed ID: 32099405
[TBL] [Abstract][Full Text] [Related]
8. SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
Pudelko L; Jaehrling F; Reusch C; Vitri S; Stroh C; Linde N; Sanderson MP; Musch D; Lebrun CJ; Keil M; Esdar C; Blaukat A; Rosell R; Schumacher KM; Karachaliou N
iScience; 2020 Dec; 23(12):101832. PubMed ID: 33305187
[TBL] [Abstract][Full Text] [Related]
9. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With
Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A
JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003
[TBL] [Abstract][Full Text] [Related]
10. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
[TBL] [Abstract][Full Text] [Related]
11. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
12. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W; Friese-Hamim M; Johne A; Stroh C; Klevesath M; Falchook GS; Hong DS; Girard P; El Bawab S
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):428-440. PubMed ID: 33818908
[TBL] [Abstract][Full Text] [Related]
13. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
14. Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report.
Makimoto G; Shimonishi A; Ohashi K; Ninomiya K; Higo H; Kato Y; Fujii M; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
Case Rep Oncol; 2022; 15(2):494-498. PubMed ID: 35702678
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Ahn L; Alexander T; Vlassak S; Berghoff K; Lemmens L
Clin J Oncol Nurs; 2022 Sep; 26(5):543-551. PubMed ID: 36108212
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
17. Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring
Hashiguchi MH; Sato T; Yamamoto H; Watanabe R; Kagyo J; Domoto H; Shiomi T
JTO Clin Res Rep; 2022 Feb; 3(2):100271. PubMed ID: 35252894
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation.
Brazel D; Zhang S; Nagasaka M
Lung Cancer (Auckl); 2022; 13():33-45. PubMed ID: 35592355
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
Xiong W; Papasouliotis O; Jonsson EN; Strotmann R; Girard P
Cancer Chemother Pharmacol; 2022 May; 89(5):655-669. PubMed ID: 35385993
[TBL] [Abstract][Full Text] [Related]
20. A case of successful desensitization treatment with tepotinib after tepotinib-induced rash.
Tamura T; Hata S; Baba T; Koyanagi T; Umeno T; Nishii K; Kuyama S
Respir Med Case Rep; 2023; 45():101911. PubMed ID: 37706029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
